文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

低资源环境下前列腺癌低剂量率近距离放疗的实施与初步结果

Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-04-11

在波多黎各这一低资源环境中回顾2008至2013年接受低剂量率近距离放疗的非转移性前列腺癌患者191例,中位随访26个月,生化失败6例(3%),2年与3年生化无失败生存率分别为97%和95.9%,未发生>2级胃肠毒性。

要点

  • 低资源环境实施LDR近距离放疗面临启动资金、转诊模式、剂量师与物理师等人员缺乏及保险报销阻力等障碍。
  • 191例非转移性前列腺癌患者中位随访26个月,PSA失败6例(3%),2年与3年生化无失败生存率分别为97%与95.9%。
  • 未发生早期或晚期>2级胃肠毒性,早期与晚期>2级泌尿生殖毒性分别仅3例(2%)与2例(1%)。

核心结论

  • 低资源环境下实施LDR近距离放疗存在特有障碍,但数据支持其作为前列腺癌可靠且有效的治疗方式。

研究设计与样本

  • 经机构批准后回顾性分析波多黎各2008至2013年接受LDR近距离放疗的非转移性前列腺癌患者病历,共191例,中位随访26个月。

主要发现

  • 191例患者中PSA失败6例(3%),2年与3年生化无失败生存率分别为97%和95.9%。
  • 未发生早期或晚期>2级胃肠毒性,早期与晚期>2级泌尿生殖毒性分别发生于3例(2%)与2例(1%)。

关键数值与推荐

  • D90覆盖定义为靶体积90%接受≥140 Gy剂量。
  • 毒性按常见不良事件术语标准(CTCAE)评估,记录>2级早期与晚期毒性。
  • 生化失败采用Kaplan-Meier分析评估无生化失败生存。

临床怎么用

  • 在低资源环境中可考虑开展LDR近距离放疗治疗非转移性前列腺癌,但需预先解决启动资金、转诊模式、剂量师与物理师等人员培训及保险报销等障碍。

局限性

  • 为单中心回顾性研究,中位随访仅26个月,目前 delineating 低资源环境实施LDR近距离放疗障碍的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In areas with limited health care, it is important to identify and implement effective treatment methods and to optimize available resources. We investigated the implementation of a low-dose-rate (LDR) brachytherapy program for the treatment of prostate cancer (PCa) in a low-resource setting such as Puerto Rico (PR), where PCa is the main cause of cancer-associated death. METHODS AND MATERIALS: After institutional approval, the medical records of patients with nonmetastatic PCa undergoing LDR brachytherapy from 2008 to 2013 were reviewed from PR. The factors analyzed included adequate D90 (radiation dose delivered to 90% of the target volume) coverage (≥140 Gy), early and late toxicity (Common Terminology Criteria for Adverse Events grade >2), and prostate-specific antigen failure. Freedom from biochemical failure was evaluated using Kaplan-Meier analysis. RESULTS: The barriers to implementation of LDR brachytherapy in a country with limited resources were identified. These included lack of access to funding for startup costs, specific referral patterns, lack of trained support staff, such as dosimetrists and physicists, and initial opposition from insurance companies for reimbursement. The initial results from 191 patients were included in the present study with a median follow-up period of 26 months. Prostate-specific antigen failure occurred in 6 patients (3%). No early or late gastrointestinal toxicity (grade >2) developed. Only 3 (2%) and 2 (1%) patients experienced early and late genitourinary toxicity (grade >2), respectively. The 2- and 3-year freedom from biochemical failure in this population was 97% and 95.9%, respectively. CONCLUSIONS: At present, limited data are available delineating the barriers faced by low-resource settings in the implementation of LDR brachytherapy. Our data highlight the issues unique to this environment and support the use of LDR brachytherapy as a reliable and effective treatment modality for patients with PCa in low-resource settings.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Echevarria MI, Naghavi AO, Abuodeh YA, et al. Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings. Int J Radiat Oncol Biol Phys. 2017. PMID: 28871987. doi:10.1016/j.ijrobp.2017.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。